[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Second Hospital of Jilin University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":96},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,74],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100642455","perioperative-myocardial-injury-in-patients-undergoing-coronary-artery-bypass-grafting-a-prospective-clinical-study-100642455",false,"NCT07650487","Perioperative Myocardial Injury in Patients Undergoing Coronary Artery Bypass Grafting: A Prospective Clinical Study","Prospective Clinical Study for Evaluation of Perioperative Myocardial Injury Using High-Sensitivity Troponin and Cardiac MRI in Patients Undergoing Coronary Artery Bypass Grafting (CABG)","Inclusion Criteria:\n\n1. Age ≥ 21 years\n2. Undergoing CABG for unstable angina\n3. Able to provide written informed consent\n4. No major cardiovascular event in the prior 6 months\n\nExclusion Criteria:\n\n1. Significant hepatic, renal, or other major organ dysfunction\n2. Pregnancy or breastfeeding\n3. Withdrawal during the study\n4. Contraindication to cardiac MRI (metal implants, claustrophobia, etc.)","ALL","21 Years","80 Years",{"count":20,"type":21},150,"ESTIMATED","OBSERVATIONAL","Perioperative myocardial injury (PMI) following coronary artery bypass grafting (CABG) is associated with postoperative morbidity, mortality, and long-term outcomes. High-sensitivity troponin assays and cardiac MRI offer reliable diagnostic tools for PMI, but evidence regarding optimal diagnostic thresholds and perioperative imaging strategy is limited. This prospective clinical study aims to determine the incidence of perioperative myocardial injury using multimodal assessments including high-sensitivity troponin, electrocardiogram, echocardiography, cardiac MRI, and perioperative cardiovascular events.",[25,26],"Myocardial Injury","Coronary Artery Disease",[28,29,30,31,26],"Perioperative Myocardial Injury","Coronary Artery Bypass Grafting","Cardiac MRI","hs-Troponin","NOT_YET_RECRUITING","2026-06-10",{"date":35,"type":36},"2026-06-16","ACTUAL",{"date":38,"type":21},"2026-07-01",{"date":40,"type":21},"2027-07-30",{"name":42,"class":43},"Second Hospital of Jilin University","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":18,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":4},"100613904","aaraarhar-vs-aartarfet-for-type-a-aortic-intramural-hematoma-100613904","NCT07272655","AAR\u002FAAR+HAR vs AAR+TAR+FET for Type A Aortic Intramural Hematoma","A Prospective, Randomized, Non-Inferiority Trial of AAR\u002FAAR+HAR Versus AAR+TAR+FET in Type A Aortic Intramural Hematoma","Inclusion Criteria:\n\n1. Age ≥ 18 years and ≤ 80 years.\n2. Diagnosis of type A aortic intramural hematoma (TAIMH).\n3. Ability to understand the study procedure and provide written informed consent.\n\nExclusion Criteria:\n\n1. Preoperative CTA shows an open or partially thrombosed (mixed) false lumen in the ascending aorta or arch.\n2. Primary tear located on the greater curvature of the aortic arch, necessitating total arch replacement.\n3. Planned concomitant major cardiac surgery (e.g., CABG, valve replacement, atrial fibrillation ablation).\n4. Previous history of aortic arch or distal aortic surgery.\n5. Severe peripheral vascular disease or cerebrovascular anatomy abnormality.\n6. Active systemic infection, malignancy, severe hepatic or renal dysfunction, or other major comorbidities with life expectancy \\\u003C 1 year or deemed unfit for complex cardiovascular surgery.\n7. Pregnancy or lactation.\n8. Severe psychiatric or cognitive disorders affecting compliance or follow-up.","18 Years",{"count":54,"type":21},400,"INTERVENTIONAL",[57],"NA","This is a prospective, randomized, non-inferiority clinical trial designed to compare the efficacy and safety of two surgical strategies for acute type A aortic intramural hematoma (TAIMH): (1) ascending aorta replacement or ascending aorta plus hemiarch replacement (AAR\u002FAAR+HAR), and (2) ascending aorta replacement with total arch replacement and frozen elephant trunk implantation (AAR+TAR+FET). Patients will be enrolled based on CTA confirmation of a completely thrombosed false lumen in the ascending aorta and aortic arch. Eligible participants will be randomized in a 1:1 ratio to either group. The primary endpoint is the rate of reintervention on the aortic arch or descending aorta from 6 to 12 months after surgery. Secondary endpoints include circulatory arrest time, aortic cross-clamp time, major adverse cardiovascular events, other perioperative complications, and total hospitalization cost. A total of 400 participants will be enrolled.",[60],"Aortic Intramural Hematoma",[62,63,64,65],"Aortic Intramural Hematoma, Type A","Hemiarch Replacement","Total Arch Replacement","Non-Inferiority Trial","2026-05-04",{"date":68,"type":36},"2026-05-08",{"date":70,"type":21},"2026-06-01",{"date":72,"type":21},"2027-10-30",{"name":42,"class":43},{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":18,"enrollmentInfo":81,"targetDuration":4,"studyType":55,"phases":82,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":44},"100597378","total-arterial-vs-mixed-grafting-in-left-coronary-cabg-100597378","NCT07057713","Total Arterial vs. Mixed Grafting in Left Coronary CABG","A Prospective, Randomized, Double-Blind Controlled Trial Comparing Total Arterial Grafting Versus Conventional Mixed Grafting in the Left Coronary Artery System During Coronary Artery Bypass Grafting (CABG)","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Diagnosed with multivessel coronary artery disease\n3. Indicated for elective coronary artery bypass grafting (CABG) involving ≥3 coronary vessels\n4. Right coronary artery stenosis \\>75%\n5. Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n1. Scheduled for concurrent cardiac procedures (e.g., valve surgery, congenital heart disease repair, aortic dissection surgery, atrial fibrillation ablation)\n2. Severe stenosis of left or right subclavian artery\n3. Unsuitable saphenous veins (e.g., bilateral varicosities)\n4. Unsuitable radial artery as assessed preoperatively\n5. History of intracranial hemorrhage or ischemic stroke within the past 14 days\n6. Severe hepatic or renal insufficiency\n7. Acute myocardial infarction within 72 hours prior to surgery\n8. History of prior CABG or other cardiac surgery",{"count":54,"type":21},[57],"This is a prospective, randomized, double-blind controlled trial comparing the clinical efficacy of total arterial grafting (internal thoracic artery and radial artery) versus conventional mixed grafting (internal thoracic artery and great saphenous vein) in the left coronary artery system during coronary artery bypass grafting (CABG). A total of 400 patients undergoing elective CABG at the Second Hospital of Jilin University will be enrolled and randomized into two groups. The primary endpoint is graft patency at 12 months postoperatively, evaluated by coronary angiography or CT angiography. Secondary outcomes include perioperative complications, major adverse cardiovascular events (MACE), and long-term clinical prognosis. The study aims to provide evidence-based guidance on optimal graft selection in CABG.",[26,29,85,86,87],"Arterial Graft","Graft Patency","Major Adverse Cardiovascular Events","2026-04-21",{"date":90,"type":36},"2026-04-23",{"date":92,"type":21},"2026-08-01",{"date":94,"type":21},"2027-12-30",{"name":42,"class":43},""]